Professional Marketing briefs

Share this article:
Doctors who use the Internet and other technologies to interact with pharma, biotech and medical device companies, has grown by 23% to 87% of the total US physician population since 2004 according to the results of a new study by Manhattan Research. According to the study, physicians would like to use more online conferences and professional online videos and show a significant interest in reading medical journals online.

Lilly announced that it will eliminate around 300 positions in its US diabetes, neuroscience and osteoporosis sales forces as it introduces a new sales model featuring smaller territories manned by a rep with greater therapeutic expertise. The new sales model will replace large territories with multiple sales partners. Part of Lilly's strategy is to help reps better connect with physicians and increase accountability.

Zogenix will co-promote Sumavel DosePro (sumatriptan injection) needle-free delivery system with Astellas Pharma US. Sumavel DosePro which received FDA approval in July 2009, is a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, a treatment that provides migraine relief within 10 minutes for some patients.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?